2008年6月12日 · The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial was designed to assess the effects on major vascular...

2009年11月1日 · The ADVANCE study has answered a number of important questions regarding glycemic control in patients with type 2 diabetes. It has clearly demonstrated that it is possible to achieve tight levels of glycemic control safely using conventional agents.

2008年3月18日 · The ADVANCE Trial is the largest-ever study aimed at investigating the effects of a treatment based on the fixed combination of an ACE-inhibitor (perindopril, 2mg) and a diuretic agent (indapamide, 0.625mg) on macrovascular and microvascular complications and deaths.

2009年1月1日 · The ADVANCE study randomized 11,140 participants at sites in Europe, Australia/New Zealand, Canada, and Asia to a strategy of intensive glycemic control (with primary therapy being the sulfonylurea gliclizide and additional medications as needed to achieve a target A1C of ≤6.5%) or to standard therapy (in which any medication but gliclizide ...

2014年10月9日 · In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril and indapamide reduced...

2008年1月5日 · Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The ADVANCE study1 claims that a regimen of perindopril and indapamide reduces vascular morbidity and mortality in patients with type 2 diabetes and one other vascular risk factor.

2011年4月30日 · New data regard the blood pressure and the glucose lowering arms, atrial fibrillation and renal outcome. Authors further report on the benefit of the perindopril/indapamide combination as well as on the best predictors of coronary and cardiovascular events in the diabetic population.

We randomly assigned 11,140 patients with type 2 diabetes to undergo either stan-dard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other...

Objectives: To determine the effects on macrovascular and microvascular disease of first, lowering blood pressure using a very-low-dose angiotensin-converting enzyme (ACE) inhibitor-diuretic combination compared with placebo; and second, intensive glucose control targeting a glycated haemoglobin A1c concentration of 6.5% or less compared with us...

Objectives: ADVANCE (Action in Diabetes and Vascular disease; preterAx and diamicroN-MR Controlled Evaluation) will examine the hypotheses that intensive blood pressure lowering (with an angiotensin-converting enzyme [ACE] inhibitor-diuretic combination) and glucose control in high-risk hypertensive or non-hypertensive individuals with type 2 ...